Below are the most recent publications written about "Flavonoids" by people in Profiles.
-
Bielory L, Tabliago NRA. Flavonoid and cannabinoid impact on the ocular surface. Curr Opin Allergy Clin Immunol. 2020 10; 20(5):482-492.
-
Selvakumar P, Badgeley A, Murphy P, Anwar H, Sharma U, Lawrence K, Lakshmikuttyamma A. Flavonoids and Other Polyphenols Act as Epigenetic Modifiers in Breast Cancer. Nutrients. 2020 Mar 13; 12(3).
-
He G, Li J, Pang X, Wang H, Jin H, He J, Fang SM, Chang YX. A Beta/ZSM-22 Zeolites-Based-Mixed Matrix Solid-Phase Dispersion Method for the Simultaneous Extraction and Determination of Eight Compounds with Different Polarities in Viticis Fructus by High-Performance Liquid Chromatography. Molecules. 2019 Sep 20; 24(19).
-
Fanelli Kuczmarski M, Sebastian RS, Goldman JD, Murayi T, Steinfeldt LC, Eosso JR, Moshfegh AJ, Zonderman AB, Evans MK. Dietary Flavonoid Intakes Are Associated with Race but Not Income in an Urban Population. Nutrients. 2018 Nov 13; 10(11).
-
Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7?+?3) in newly diagnosed high-risk acute myeloid leukemia (AML). Leuk Res. 2018 09; 72:92-95.
-
LaCerte C, Ivaturi V, Gobburu J, Greer JM, Doyle LA, Wright JJ, Karp JE, Rudek MA. Exposure-Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients. Clin Cancer Res. 2017 Jul 15; 23(14):3592-3600.
-
Morales F, Giordano A. Overview of CDK9 as a target in cancer research. Cell Cycle. 2016; 15(4):519-27.
-
Zhang Y, Li X, Ciric B, Ma CG, Gran B, Rostami A, Zhang GX. Therapeutic effect of baicalin on experimental autoimmune encephalomyelitis is mediated by SOCS3 regulatory pathway. Sci Rep. 2015 Nov 30; 5:17407.
-
Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 Sep; 100(9):1172-9.
-
Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala H, Hogan KT, Colevas AD, Doyle LA, Figg WD, Coppola D, Roberts JD, Sullivan D, Grant S. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res. 2014 Nov 15; 20(22):5652-62.